Bank Of America Corp Inhibrx, Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Inhibrx, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 741,591 shares of INBX stock, worth $10.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

741,591

Previous 692,980 7.01%

Holding current value

$10.5 Million

Previous $26.3 Million 1.55%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $1.59 Million - $1.92 Million	48,611 Added 7.01%	741,591 $25.9 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $8.56 Million - $22.4 Million	590,137 Added 573.82%	692,980 $26.3 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $1.42 Million - $2.33 Million	-83,898 Reduced 44.93%	102,843 $2.67 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $743,055 - $1.09 Million	40,274 Added 27.5%	186,741 $3.52 Million
Q4 2022 Feb 10, 2023	BUY	$20.18 - $33.33 $374,883 - $619,171	18,577 Added 14.53%	146,467 $3.61 Million

Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.35 Million - $2.87 Million	116,255 Added 999.18%	127,890 $2.3 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $398,165 - $1.18 Million	-46,733 Reduced 80.07%	11,635 $132,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $238,222 - $517,166	11,977 Added 25.82%	58,368 $1.3 Million
Q4 2021 Feb 08, 2022	BUY	$26.75 - $46.02 $724,630 - $1.25 Million	27,089 Added 140.34%	46,391 $2.03 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $289,821 - $435,193	11,510 Added 147.72%	19,302 $643,000
Q2 2021 Sep 13, 2021	BUY	$14.69 - $27.52 $114,464 - $214,435	7,792 New	7,792 $214,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Inhibrx, Inc. Transaction History